stockmarketproxy
/
PTGXNasdaq SEC EDGAR

Protagonist Therapeutics, Inc

Pharmaceutical Preparations·NEWARK, CA·FY end 12/31·CIK 1377121
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue——————
Gross Profit——————
Operating Income-$158.1M$252.8M-$93.7M-$131.4M-$125.8M
Net Income-$130.1M$275.2M-$79.0M-$127.4M-$125.6M
Operating CF$57.7M$184.2M-$70.2M-$108.1M-$107.9M
Capex$1.6M$1.4M$609.0K$795.0K$1.1M
Free Cash Flow$56.1M$182.8M-$70.8M-$108.9M-$109.0M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin——————
Net Margin——————
FCF Margin——————
R&D / Revenue——————
Effective Tax-0.6%1.5%0.0%0.0%0.0%
Debt / Equity——————
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
PTGX
30:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
PTGX
$13M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
PTGX
—
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%